摘要
背景:妊娠特异性β1-糖蛋白(PSG)长期以来被认为是滋养层质量和胚胎生存力标记。然而,PSG的生物学作用仍然是模糊的,并且与其他胎儿胎盘蛋白的结构/功能关系以及对药物设计的影响还没有审查。这篇综述总结和讨论了PSGs 45年研究的进展,重点关注最新成就和未来调查的挑战。 方法:进行文献检索以回顾大多数最近的PSG研究,重点是使用高通量整合蛋白质组学分析技术,系统生物学和生物信息学方法,增强新的生物标志物和药物靶点发现以及蛋白质结构/活性分析。 结果:当PSG测量与其他胎盘衍生的蛋白质:hCG,hPL,PAPP-A和proMBP组合时,临床意义和筛选性能改善。然而,蛋白质共表达和共定位数据的分析和PSG参与蛋白质相互作用网络正在引入发现新型,特异性和高敏感性,妊娠/癌症生物标志物。尽管PSG的生物学作用尚未完全了解,但有证据表明它们表现出免疫调节,抗炎和促血管生成作用。结构/功能关系的研究表明,PSGs可以协同/协调的方式与许多调节蛋白包括甲胎蛋白和转化生长因子-β;这通过存在保守的短线性基序(SLiM)如RGD,PXXP和AFP14-20样(YXCX)的存在提供。 结论:PSG衍生的肽可以用作设计模拟参与蛋白质 - 蛋白质相互作用的SLiM以抑制结构域基序结合和阻断细胞信号传导和/或发挥免疫调节,抗炎和促血管生成作用的新药物的理论依据。
关键词: 妊娠特异性β1-糖蛋白,生物标记谱,胚胎/胎盘发育,滋养细胞疾病,结构/功能关系,短线性基序,新药物设计。
Current Medicinal Chemistry
Title:Pregnancy-Specific β1-Glycoproteins: Combined Biomarker Roles, Structure/Function Relationships and Implications for Drug Design
Volume: 24 Issue: 3
关键词: 妊娠特异性β1-糖蛋白,生物标记谱,胚胎/胎盘发育,滋养细胞疾病,结构/功能关系,短线性基序,新药物设计。
摘要: Background: Pregnancy specific β1-glycoproteins (PSGs) have long been recognized as trophoblast quality and embryo viability markers. However, biological roles of PSGs remain obscure, and structure/function relationships to other feto-placental proteins as well as implications for drug design have not been reviewed. This review summarizes and discusses advances in 45-year studies of PSGs with focus on the latest achievements and the challenges for future investigations.
Methods: Literature search was performed to review the majority of recent PSG studies with emphasis on usage of high-throughput integrated proteomic profiling technologies, systems biology and bioinformatics approaches that enhance novel biomarker and drug target discovery as well as protein structure/activity analysis. Results: Clinical significance and screening performance improved when PSG measurements were combined with those of other placenta-derived proteins: hCG, hPL, PAPP-A, and proMBP. Nevertheless, analysis of protein co-expression and co-localization data and the involvement of PSGs in protein interaction networks are being introduced to discover novel, specific and high-sensitive, gestational/cancer biomarkers. Despite biological roles of PSGs are not fully understood, there are evidences of that they exhibit immunomodulatory, antiinflammatory and proangiogenic effects. Investigation of structure/function relationships showed that PSGs may function in cooperative/coordinated manner with numerous regulatory proteins including alpha-fetoprotein and transforming growth factors-β; this is provided by the presence of conserved short linear motifs (SLiMs) such as RGD, PXXP and AFP14-20-like (YXCX) ones. Conclusion: PSG-derived peptides may be used as a rationale to design novel drugs that mimic SLiMs involved in protein-protein interactions to inhibit domain-motif binding and to block cell signaling, and/or exert immunomodulatory, anti-inflammatory and proangiogenic effects.Export Options
About this article
Cite this article as:
Pregnancy-Specific β1-Glycoproteins: Combined Biomarker Roles, Structure/Function Relationships and Implications for Drug Design, Current Medicinal Chemistry 2017; 24 (3) . https://dx.doi.org/10.2174/0929867324666161123090554
DOI https://dx.doi.org/10.2174/0929867324666161123090554 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Current Drug Targets Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Organ Preservation by the Association of Chemotherapy and Radiotherapy in Invasive Bladder Cancer
Current Drug Therapy Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety <i>Circular RNA NF1-419</i> Inhibits Proliferation and Induces Apoptosis by Regulating Lipid Metabolism in Astroglioma Cells
Recent Patents on Anti-Cancer Drug Discovery Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Novel Antimicrobial Agents for the Management of Maxillofacial and Neck Infections
Recent Patents on Anti-Infective Drug Discovery Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Metal Ions and Metal Complexes in Alzheimer’s Disease
Current Pharmaceutical Design DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology Chemoprotective and Carcinogenic Effects of tert-Butylhydroquinone and Its Metabolites
Current Drug Metabolism Combination of Salinomycin and AZD3463 Reveals Synergistic Effect on Reducing the Viability of T98G Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry